From the Journals

More evidence links increased BMI to higher multiple myeloma risk


 

FROM BRITISH JOURNAL OF CANCER

Dr. Marinac and her team identified a total of 205 men from the HPFS cohort and 370 women (325 NHS, 45 WHS) with confirmed diagnoses of MM. The BMIs of those participants ranged from 23.8-25.8 kg/m2 at baseline and from 21.3-23.0 kg/m2 in young adulthood. Across all cohorts, each 5 kg/m2 increase in cumulative average adult BMI significantly increased the risk of MM by 17% (hazard ratio, 1.17; 95% confidence interval, 1.05-1.29).

In addition, the MM risk rose almost 30% for every 5 kg/m2 increase in young adult BMI (HR, 1.28; 95% CI, 1.12-1.47). Increased risk was not strictly related to changes in BMI but to incremental weight gain since young adulthood. Researchers found that for each 5 kg increase in weight since young adulthood, the risk of developing MM increased by 4%. (pooled HR, 1.04; 95% CI, 1.00-1.08; P = 0.03).

The study confirmed correlations between weight gain and increased MM risk, however, it also had certain limitations. For example, much of the data concerning weight, height, and physical activity were all self-reported. Another limitation is the sociodemographic heterogeneity of the study population.

Despite those limitations, Dr. Marinac emphasized that the study results add to evidence concerning weight gain and MM risk.

Recommended Reading

FDA alert: pembrolizumab ups mortality risk in multiple myeloma
Federal Practitioner
New antibodies, drugs for refractory and relapsed myeloma are effective in patients over 65
Federal Practitioner
Tailored approaches to relapsed/recalcitrant myeloma found within NCCN guidelines
Federal Practitioner
Treatment and Management of Multiple Myeloma (FULL)
Federal Practitioner
Cyclophosphamide after transplant reduced GVHD in myeloma patients
Federal Practitioner
Late-breaking abstracts highlight treatment advances in CLL, myeloma, and more
Federal Practitioner
Anti-BCMA CAR T-cell therapy being fast tracked at FDA
Federal Practitioner
Continue to opt for HDT/ASCT for multiple myeloma
Federal Practitioner
Meningococcal Arthritis Masking as Possible Myeloma
Federal Practitioner
In myeloma, third ASCT is a viable option
Federal Practitioner